This adaptive process involves epigenetic reprogramming and transcriptomic remodeling, often driven by loss-of-function alterations in key tumor suppressors such as PTEN, RB1, and TP53, which decouple tumor growth from AR dependency (1–3). The gene discussed is TP53; the disease is neoplasm.